Mukulika Bose

This study shows DLL3 expression level predicts response and long-term survival in SCLC patients treated with tarlatamab.

This study identifies YAP1-positive cells in relapsed SCLC that exhibit drug tolerance and transition from SCLC to LCNEC-like features, losing some targets but gaining others.

This study uses CyTOF to profile circulating tumor cells in SCLC patients, identifying subtype-specific markers and treatment response correlations.